Results 21 to 30 of about 24,464,352 (186)

Ceftazidime-avibactam treatment dilemma of bla KPC−2-containing Klebsiella pneumoniae due to the development of co-existence of mixed strains carrying bla KPC−2 or bla KPC−33 in lung transplant recipients

Annals of Clinical Microbiology and Antimicrobials
Background Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant threat to immunocompromised populations, including lung transplant recipients.
Zichen Lei, Ziyao Li, Yulin Zhang, Lingbing Zeng, Yongli Wu, Feilong Zhang, Xinrui Yang, Xinmeng Liu, Qi Liu, Yiqun Ma, Binghuai Lu   +10 more
doaj   +2 more sources

In silico identification and experimental validation of hits active against KPC-2 β-lactamase. [PDF]

PLoS ONE, 2018
Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, being characterized by a broad ...
Raphael Klein, Pasquale Linciano, Giuseppe Celenza, Pierangelo Bellio, Sofia Papaioannou, Jesus Blazquez, Laura Cendron, Ruth Brenk, Donatella Tondi   +8 more
doaj   +2 more sources

KPC-2-NDM-1-producing Serratia marcescens: first description in Peru

New Microbes and New Infections, 2022
Two clonal extensively-resistant S. marcescens were isolated in Peru. The presence and transferability of extended-spectrum β-lactamases and IMP, KPC, NDM, OXA-48 and VIM were determined.
Barbara Ymaña, Nestor Luque, Maria J. Pons, Joaquim Ruiz   +3 more
doaj   +2 more sources

Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Klebsiella pneumoniae ST11 is related to low mutation rates

Microbiology Spectrum
Klebsiella pneumoniae strains that produce Klebsiella pneumoniae Carbapenemase (KPC) variants displaying resistance to ceftazidime-avibactam (CZA) often remain susceptible to meropenem (MEM), suggesting a potential therapeutic use of this carbapenem ...
Jesus G. M. Pariona, Felipe Vásquez-Ponce, Johana Becerra, Thais Martins-Gonçalves, Eva M. M. Pariona, Fabio T. Madueño, Fernanda Esposito, Aline V. de Lima, Jorge L. Mello Sampaio, Rodrigo S. Galhardo, Nilton Lincopan   +10 more
doaj   +2 more sources

A High-Affinity Nanobody Selectively Recognizing KPC-2/KPC-3: Biochemical and Structural Insights. [PDF]

Biomolecules
International audienceCarbapenemase-producing bacteria, particularly those expressing the KPC-3 variant, pose a critical global health threat due to their resistance to nearly all β-lactam antibiotics, including carbapenems.
Hamdi E, Khamessi O, Piccirilli A, Dhaouadi S, Zarrouk S, Brisdelli F, Dabbek H, Saihi MH, Bouhaouala-Zahar B, Ben Abderrazek R, Perilli M.   +10 more
europepmc   +2 more sources

The effect of Lactobacillus with prebiotics on KPC-2-producing Klebsiella pneumoniae

Frontiers in Microbiology, 2022
ObjectivesThis study investigated the inhibitory effect ofLactobacillusspp. with prebiotics againstKlebsiella pneumoniaecarbapenemase-2 (KPC-2)-producingKlebsiella pneumoniaeusing bothin vitroexperiments and animal models.MethodsThirty-threeLactobacillusspp.
Hung-Jen Tang, Hung-Jen Tang, Chi-Chung Chen, Ying-Chen Lu, Hui-Ling Huang, Hung-Jui Chen, Yin-Ching Chuang, Chih-Cheng Lai, Chien-Ming Chao   +8 more
openaire   +3 more sources

First Description of KPC-2-Producing Pseudomonas putida in Brazil [PDF]

Antimicrobial Agents and Chemotherapy, 2012
ABSTRACT This work reports the identification of the first case of a KΡC-2-producing Pseudomonas putida isolate (PP36) in Brazil. The PP36 isolate was resistant to all the antimicrobials tested except polymyxin B.
Anna C S, Almeida, Marinalda A, Vilela, Felipe L S, Cavalcanti, Willames M B S, Martins, Marcos A, Morais, Marcia M C, Morais   +5 more
openaire   +2 more sources

Vaccination with Carbapenemase KPC-2 and Virulence Factor Pal Provided Robust Protection Against <i>Klebsiella pneumoniae</i> Lung Infection. [PDF]

Vaccines (Basel)
Objectives: Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) merges multidrug resistance with hypervirulence, posing unprecedented therapeutic challenges. This study aimed to evaluate the efficacy of a recombinant fusion protein vaccine,
Jiang S, Yuan Y, Tang Y, Liao J, Chen Z, Yu X, Zhu J, Gou Q, Jing H, Li X, Zhao Z, Xu Y, Zou Q, Zhang J.   +13 more
europepmc   +2 more sources

Emergence of KPC-113 and KPC-114 variants in ceftazidime-avibactam-resistant Klebsiella pneumoniae belonging to high-risk clones ST11 and ST16 in South America

Microbiology Spectrum, 2023
Two novel variants of Klebsiella pneumoniae carbapenemase (KPC) associated with resistance to ceftazidime-avibactam (CZA) and designated as KPC-113 and KPC-114 by NCBI were identified in 2020, in clinical isolates of Klebsiella pneumoniae in Brazil ...
Felipe Vásquez-Ponce, Jessica Bispo, Johana Becerra, Herrison Fontana, Jesus G. M. Pariona, Fernanda Esposito, Bruna Fuga, Flavio A. Oliveira, Florencia Brunetti, Pablo Power, Gabriel Gutkind, Angelica Zaninelli Schreiber, Nilton Lincopan   +12 more
doaj   +1 more source

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland [PDF]

Antimicrobial Agents and Chemotherapy, 2009
Plasmidic KPC β-lactamases in gram-negative pathogens are of the highest clinical and epidemiologic concern, conferring resistance to all β-lactams, including carbapenems (15, 18). The main KPC producer is Klebsiella pneumoniae, but other species are being identified as well (15).
Anna, Baraniak, Radosław, Izdebski, Małgorzata, Herda, Janusz, Fiett, Waleria, Hryniewicz, Marek, Gniadkowski, Izabela, Kern-Zdanowicz, Krzysztof, Filczak, Urszula, Łopaciuk   +8 more
openaire   +2 more sources